Alkem Laboratories Ltd

Alkem Laboratories Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 5692, up 1.19% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.09% on the day, quoting at 25459.95. The Sensex is at 82146.86, down 0.16%. Alkem Laboratories Ltd has dropped around 1.08% in last one month. Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has dropped around 6.32% in last one month and is currently quoting at 23051.85, up 0.49% on the day. The volume in the stock stood at 50099 shares today, compared to the daily average of 1.38 lakh shares in last one month. The benchmark March futures contract for the stock is quoting at Rs 5716, up 1.11% on the day. Alkem Laboratories Ltd is up 23.4% in last one year as compared to a 12.93% spurt in NIFTY and a 14.67% spurt in the Nifty Pharma index.The PE of the stock is 30.35 based on TTM earnings ending December 25.Powered by Capital Market - Live

Alkem Laboratories announced that the United States Food and Drug Administration (USFDA) has completed a Pre-Approval Inspection (PAI) on 13 February, 2026 at the manufacturing facility of Enzene Biosciences (Enzene), a subsidiary of the Company in India located at Chakan, Pune. At the conclusion of the inspection, the USFDA issued a Form 483 with 6 procedural observations. Enzene has achieved Zero observations related to data integrity - a critical validation of Enzene's quality systems and the reliability of regulatory filings. Enzene is in the process of preparing and submitting its response to the USFDA within the stipulated timeline and has initiated appropriate corrective and preventive actions. Powered by Capital Market - Live

At the conclusion of the inspection, the USFDA issued a Form 483 with 6 procedural observations. Enzene has achieved zero observations related to data integrity ' a critical validation of Enzen's quality systems and the reliability of regulatory filings. Enzene is currently preparing its response to the USFDA within the stipulated timeline and has initiated appropriate corrective and preventive actions to address the observations. Alkem Laboratories is engaged in the pharmaceutical business with global operations. The company is engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company's consolidated net profit rose 2% to Rs 653.53 crore in Q3 FY26, compared with Rs 640.79 crore posted in Q3 FY26. Net sales jumped 10.7% YoY to Rs 3,736.82 crore in the quarter ended 31 December 2025. Shares of Alkem Laboratories added 1.38% to currently trade at Rs 5,475.85 on the BSE. Powered by Capital Market - Live

Alkem Laboratories announced that the Board of Directors of the Company at its meeting held on 13 February 2026, inter alia, have recommended the interim dividend of Rs 43 per equity Share (i.e. 2150%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Net profit of Alkem Laboratories rose 1.63% to Rs 636.02 crore in the quarter ended December 2025 as against Rs 625.82 crore during the previous quarter ended December 2024. Sales rose 10.74% to Rs 3736.82 crore in the quarter ended December 2025 as against Rs 3374.28 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales3736.823374.28 11 OPM %22.1622.51 - PBDT929.00816.35 14 PBT833.99731.07 14 NP636.02625.82 2 Powered by Capital Market - Live

Alkem Laboratories Ltd gained for a fifth straight session today. The stock is quoting at Rs 5888.5, up 1.32% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.09% on the day, quoting at 25911.2. The Sensex is at 84112.36, down 0.19%. Alkem Laboratories Ltd has risen around 0.37% in last one month. Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has risen around 1.49% in last one month and is currently quoting at 22210.5, up 0.54% on the day. The volume in the stock stood at 54723 shares today, compared to the daily average of 1.23 lakh shares in last one month. The benchmark February futures contract for the stock is quoting at Rs 5864, up 1.6% on the day. Alkem Laboratories Ltd is up 25.06% in last one year as compared to a 12.44% spurt in NIFTY and a 5.62% spurt in the Nifty Pharma index.The PE of the stock is 31.09 based on TTM earnings ending September 25.Powered by Capital Market - Live

Alkem Laboratories Ltd is up for a third straight session today. The stock is quoting at Rs 5772.5, up 1.56% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.54% on the day, quoting at 25832.9. The Sensex is at 83979.52, up 0.48%. Alkem Laboratories Ltd has slipped around 1.61% in last one month. Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has slipped around 2.02% in last one month and is currently quoting at 21961.35, up 1.13% on the day. The volume in the stock stood at 1.27 lakh shares today, compared to the daily average of 1.19 lakh shares in last one month. The benchmark February futures contract for the stock is quoting at Rs 5758, up 1.66% on the day. Alkem Laboratories Ltd is up 20.24% in last one year as compared to a 10.48% jump in NIFTY and a 2.51% jump in the Nifty Pharma index.The PE of the stock is 30.4 based on TTM earnings ending September 25.Powered by Capital Market - Live

Alkem Laboratories Ltd fell for a fifth straight session today. The stock is quoting at Rs 5432, down 2.39% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.25% on the day, quoting at 24887.8. The Sensex is at 81014.79, up 0.36%.Alkem Laboratories Ltd has eased around 2.17% in last one month.Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has eased around 6.26% in last one month and is currently quoting at 21535.3, down 1% on the day. The volume in the stock stood at 36448 shares today, compared to the daily average of 1.21 lakh shares in last one month. The benchmark February futures contract for the stock is quoting at Rs 5435.5, down 1.99% on the day. Alkem Laboratories Ltd jumped 7.6% in last one year as compared to a 6.54% rally in NIFTY and a 0.2% fall in the Nifty Pharma index.The PE of the stock is 29.73 based on TTM earnings ending September 25.Powered by Capital Market - Live

Alkem Laboratories will hold a meeting of the Board of Directors of the Company on 13 February 2026.Powered by Capital Market - Live

Alkem Laboratories announced the launch of Renocia cyclical therapy kit, a scientifically-designed weekly nutritional supplementation regimen to support hair growth, strengthen hair follicles and manage hair loss. The supplements in the kit are made using only vegetarian-sourced ingredients. Renocia cyclical therapy kit contains a set of nutritional supplements, including vitamins, minerals, and amino acids, each to be taken on designated days of the week. This structured weekly protocol enables better nutrient absorption and utilisation. Alkem has a growing portfolio of products in the dermatology segment, which includes skin and hair care. Under the Renocia brand, the company offers several products for hair care such as hair revitalizing shampoo, conditioner and serum, as well as oral supplements. Powered by Capital Market - Live